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Abstract
Aim: Currently, there is no consensus on the retreatment recommendation of chronic hepatitis B (CHB) patients
with viral rebound after cessation of treatment. In the search of reasonable treatment, we compared the efficacy
and safety of adefovir (ADV) plus lamivudine (LAM) and LAM alone for the retreatment of patients with viral
relapse but without genotypic resistance after cessation of LAM.
Methods: This is a prospective controlled study, and a total of 53 hepatitis B e antigen (HBeAg)-positive patients
with viral rebound but without resistance were received either LAM plus ADV or LAM alone treatment.
Results: After 1-year treatment, more patients who received LAM plus ADV than those who received LAM alone
had ALT normalization (84% versus 53.6%, P = 0.018) or HBV DNA levels below 1000 copies/mL (80% versus 42.9%,
P < 0.006). Seven patients receiving LAM plus ADV had HBeAg seroconversion, as compared with 0 in patients
receiving ALM alone (28% versus 0%, P = 0.003). During 1-year retreatment, five patients receiving LAM alone had
virological breakthrough and all of them had LAM resistance strains (rtM204V/I), while no LAM- or ADV- associated
resistance strains were detected in patients receiving LAM plus ADV. All patients receiving LAM plus ADV were well
tolerated, and no serious side effects were noted.
Conclusions: Patients treated with LAM plus ADV exhibited significantly greater virological, biochemical and
serological responses compared with LAM alone. These data suggested that combination of LAM plus ADV would
be a good option for the retreatment of CHB patients with viral relapse after cessation of LAM.
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Background
Estimated 350~400 million individuals worldwide are
chronically infected with hepatitis B virus (HBV)[1], and
chronic hepatitis B(CHB) can progress to cirrhosis,
hepatocellular carcinoma (HCC), and death[2]. Antiviral
therapy is used in CHB to minimize the liver damage
and progression of disease[3], but total eradication of
the HBV is seldom achieved by current treatment, espe-
cially for patients who infected HBV in early childhood.
Nucleos(t)ide analogs approved for treatment of CHB
include lamivudine (LAM), adefovir (ADV), entecavir, tel-
bivudine and tenofovir, and they have been considered to
have a good effect in suppressing virus replication with
few side effects[4]. In general, HBeAg seroconversion is an
important end point for HBeAg-positive patients, which is
associated with sustained remission[5,6]; and international
guidelines suggested that early withdrawal of antiviral
therapy, without reaching sustainable serological response,
would lead to a very high risk of relapse[4]. In fact, a
wealth of clinical experience also suggested the problem of
viral relapse after drug withdrawal could not be ignored
[7-9]. Some investigators had reported that viral load
rebound is common in CHB patients receiving nucleos(t)
ide analogs and the relapse rates would be high to 70%
[8,10,11]. However, nearly 40% of the relapses or virologi-
cal breakthroughs were not related to antiviral drug resis-
tance. For example, due to the poverty, many CHB
patients in Asia cannot afford their long-term medication,
a n dt h e ya l w a y st e r m i n a t e dt h e i rt r e a t m e n tj u s tw h e n
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any medium, provided the original work is properly cited.reaching virological response irrespective of the occur-
rence of HBeAg seroconversion. How to therapy those
patients with viral relapse has become an urgent problem
that we have to face[12]. Unfortunately, there is no con-
sensus on the retreatment of viral relapse with or without
resistance after cessation of nucleos(t)ide analogs treat-
ment. And it is still unknown whether there is significant
difference between original drug monotherapy or com-
bined with other drugs without cross-resistance.
Current study was designed to compare the efficacy
and safety of LAM plus ADV with that of LAM alone
again in CHB patients with viral relapse after cessation
of previous LAM treatment.
Results
Characteristics of the study patients
A total of 53 HBeAg-positive CHB patients were analyzed
in the study, which comprised of 25 patients in LAM
plus ADV and 28 patients in LAM alone retreatment
(Figure 1). The demographic and disease parameters were
well matched at baseline of retreatment between two
groups, which were described in detail in table 1.
Biochemical response
Serum ALT levels declined in both treatment groups,
but ALT level was normalized in a higher proportion of
LAM plus ADV than LAM alone retreatment in total.
At 6 and 12 months after retreatment, normal ALT was
achieved in 76% (19/25) and 84% (21/25) of patients
receiving LAM plus ADV, and in 35.7%(10/28) and
53.6% (15/28) of patients receiving LAM alone, respec-
tively (Figure 2). The difference in ALT normalization
between two groups was significant at year 1(84% vs
53.6%, p = 0.018).
Figure 1 Flow chart of patients selected in this study.
Table 1 Baseline Characteristic of the study population
Characteristic LAM plus ADV
(N = 25)
LAM
(N = 28)
P value
Male sex -no. (%) 20(80%) 21(75%) 0.664
Age - yr* 35.48 36.81 0.176
ALT - IU/L* 149.52 136.25 0.247
HBV DNA - log10 copies/ml* 5.89 5.96 0.812
Previous LAM therapy- yr* 3.60 3.88 0.115
*Expressed as mean
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The reduction in serum HBV DNA levels from baseline
of retreatment during the first year of observation per-
iod was greater in LAM plus ADV than in LAM alone
retreatment (Figure 3). At 6 months, the proportion of
patients with virological response (HBV DNA < 3 log
copies/ml) was achieved in 60% (15/25) of patients
receiving LAM plus ADV retreatment as compared to
32.1% (9/28) of patients receiving LAM alone. At 12
months, the proportion of patients with virological
response was achieved in 80% (20/25) of patients receiv-
ing LAM plus ADV as compared to 42.9% (12/28) of
patients receiving LAM alone. The difference in virolo-
gical response between two groups was statistic signifi-
cant at 6 and12 months, respectively (P = 0.042 for
month 6 and P = 0.006 for month 12).
HBeAg response
More patients receiving LAM plus ADV retreatment had
HBeAg seroconversion as compared to patients receiving
LAM alone retreatment at month 12 (Figure 4), and the
difference in HBeAg seroconversion between two groups
was significant (7/25 versus 0/28, P = 0.003). Additionally,
significant more patients receiving LAM plus ADV
obtained HBeAg loss as compared to patients receiving
LAM alone at month 12(9/25 versus 1/28, P = 0.004)
(Figure 4).
Breakthrough and resistance
Viral breakthrough was found in 5 patients receiving
LAM alone retreatment during the 1-year observation
period, and the mutations of rtM204V were found in 3
patients and rtM204I were found in 2 patients at year 1
of retreatment. In LAM plus ADV retreatment patients,
no viral breakthrough were found and no LAM or ADV
associated mutations were detected.
Safety
Majority of patients were well tolerated in two retreat-
ment groups. Among patients receiving LAM plus ADV,
only1 patient had serum creatinine slightly increasing
but there was no discontinuation due to this adverse
event. Elevations in ALT were observed less frequently
in LAM plus ADV group than LAM alone in group.
ALT flares during the first year of treatment were in 5
patients with LAM alone and 1 patient with LAM plus
ADV. In LAM plus ADV group, all the ALT flares were
associated with toil; while in LAM alone retreatment
group, all the ALT flares were associated with HBV
DNA flares. Between two groups, none hepatocellular
carcinoma was reported.
Discussion
Although LAM is not recommended as first line therapy
for CHB in the American Association for Study of Liver
Disease (AASLD) CHB guidelines[4], and the European
Association for Study of Liver (EASL) CHB guidelines
[13], which recommend oral nucleosides or nucleotides
Figure 2 Biochemical response rates of patients receiving ADV
+LAM or LAM alone during the first year of retreatment.
Figure 3 Virological response rates of patients receiving ADV
+LAM or LAM alone during the first year of retreatment.
Figure 4 HBeAg loss and seroconversion rates of patients
receiving ADV+LAM or LAM alone during the first year of
retreatment.
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first line monotherapy, LAM is still widely used in Asia
due to cost constraints[14]. Thus, it is necessary for us
to concern about the re-treatment issues of patients
with viral relapse after discontinuation of LAM mono-
therapy. Unfortunately, the retreatment options for viral
relapse are still in doubt. In clinical practice, a variety of
retreatment strategies have been applied, including back
t ot h e i ro r i g i n a ld r u g ,s w i t c ht oa n o t h e rd r u g s ,o rt w o
or more drugs in combination.
Theoretically, if there were no evidence of antiviral
resistance of original agent, it seemed reasonable to
back to their original drug for retreatment. However,
this hypothesis was recently questioned by clinicians.
Evidence already had showed that HBV exists in form of
quasi-species in patients with chronic hepatitis B[15],
and because of the sensitivity and specificity limitation
of detection, drug-resistance strains sometimes could
not be detected in time, especially when its proportion
was less than 20% in the pool of viral quasi-species
[16,17]. Thus, it is not difficult to conclude that before
the drug-resistance strains reach a high number, they
may not be detected in patients with viral relapse after
cessation of antiviral treatment[16]. But it is worth men-
tioning that those inferior strains would be easily devel-
oped to predominant strains with antiviral resistance by
positive selection of antiviral agents [18,19]. Taking into
account of the above reasons, when viral relapse occurred
after cessation of treatment, switch to agents with high
genetic barrier or combination of two or more agents
without cross-resistance mayb eg o o do p t i o n sf o rp r e -
venting the occurrence of drug resistance[9,20].
In this study, we explored and compared retreatment
options for chronic hepatitis B patients with viral relapse
after cessation of LAM. After 1 year retreatment, the
proportion of undetectable HBV DNA was achieved in
80% of patients receiving LAM plus ADV as compared
to 42.9% of patients receiving LAM alone. Moreover,
higher proportion of ALT normalization and HBeAg
seroconversion were also reached in LAM plus ADV
retreatment group. Several other studies also had
reported that the combination of LAM and ADV could
lead to effective viral suppression in most cases after
development of viral breakthrough due to LAM mono-
therapy[21,22]; and patients receiving LAM plus ADV
combination therapy have a lower risk of developing
genotypic resistance to ADV[22]. In our study, patients
receiving combination therapy of LAM and ADV were
well tolerated, and no viral breakthrough was reported
and no LAM- or ADV-associated resistant strains were
detected. In contrast, among 28 patients receiving LAM
alone, five patients experienced a viral breakthrough and
LAM-associated resistant strains were detected in all of
them. Those findings gave us another hint that the com-
bination of LAM plus ADV was associated with lower
antiviral resistance compared with LAM alone. In fact,
for some special populations with chronic hepatitis B,
the combination of agents without cross-resistance had
been clearly put forward by authoritative guidelines
[4,13], and data from many clinical observational trials
also suggested combination therapy would bring more
benefits to nucleosides or nucleotides-refractory CHB
patients.
At present, majority of clinical studies on LAM plus
ADV combination therapy were for HBeAg-negative
patients, and few studies on HBeAg-positive patients
reported the combination of these agents had no syner-
gistic on HBeAg seroconversion. But in our study,
among 25 patients receiving combination therapy of
LAM plus ADV, we delighted to found that 9 patients
obtained HBeAg loss and 7 patients obtained HBeAg
seroconversion, which were significant higher to that of
patients receiving LAM alone. However, because of the
limited sample size and short observation time, we cur-
rently cannot conclude that the combination of ADV
plus LAM could increase the rate of HBeAg seroconver-
sion as compared to single nucleoside or nucleotide
analogue.
In conclusion, the current study showed that CHB
patients with viral relapse after cessation of LAM
retreated by LAM plus ADV exhibited significantly
greater virological, biochemical and serological
responses compared with LAM alone. These findings
indicated that combination of LAM plus ADV would be
a good option for the retreatment of CHB patients with
viral relapse after cessation of LAM.
Methods
Patients
Outpatients from Chengdu Military General Hospital,
with viral relapse after cessation of LAM treatment were
screened, of who included in this study should also meet
the following criteria: serum hepatitis B e antigen
(HBeAg) positive; serum HBV DNA load above 1000
copies/ml; alanine aminotransferase (ALT) levels
between 2 and 10 times the upper normal level. And
patients who fulfilled one of the following criteria should
be excluded: evidence of LAM associated resistance
(rtM204V or rtM204I); presence of serum antibodies
against hepatitis C virus (HCV), or human immuno-
deficiency virus (HIV); breast-feeding, pregnancy or
inadequate contraceptive measures; other acquired or
inherited causes of liver disease; coexisting serious medi-
cal disease; advanced liver disease(including decompen-
sated cirrhosis with ascites, severe hepatitis, and hepatic
carcinoma).
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This is a prospective controlled study, aimed to evaluate
and compare the efficacy of LAM plus ADV with that
of LAM alone retreatment in patients with viral relapse
after cessation of LAM antiviral therapy. All included
patients were administered 100 mg of LAM plus 10 mg
of ADV (GlaxoSmithKline) or 100 mg of LAM alone
daily according to patients’ choice, and they were fol-
lowed up in outpatient clinic of hospital. Clinical data
were collected at baseline, and every 3 months after
retreatment. The primary efficacy outcomes were ALT
normalization, reduction in HBV DNA, and seroconver-
sion of HBeAg. Second efficacy outcome was antiviral
resistance.
This study was approved by Chengdu Military General
Hospital’s institutional review board and was conducted
in accordance with the 1975 Declaration of Helsinki.
Serum assay methodology
HBeAg and serum HBV DNA were measured with the
use of Enzyme-Linked Immunosorbent Assay (InTec
Technology Co., Ltd., Xiamen, China) and real-time
PCR-based quantification assays(DA AN gene Co., Ltd.,
Guangzhou, China) according to the manufacturer’s
instructions, respectively. Serum ALT and Creatinine
(Cr) were measured using automatic biochemistry analy-
zer according to standard laboratory procedures. Anti-
viral resistance was analyzed using PCR sequencing
assay if HBV DNA no less than 1000 copies/mL after
1-year antiviral treatment.
Definition
Biochemical response was defined as a decrease in
serum ALT to within the normal range. Virological
response was defined as a decrease in serum HBV DNA
to undetectable levels by PCR assays (<1000 copies/mL).
HBeAg response was defined as a loss or seroconversion
of HBeAg in patients who were initially HBeAg positive.
Virological breakthrough was defined as an increase in
serum HBV DNA by 1 log10 (10-fold) above nadir, or
to detectable level (≥ 1000 copies/mL) after achieving
virological response during retreatment. Viral relapse
was defined as an increase in serum HBV DNA to
detectable level after achieving virological response.
Statistical analysis
Quantitative variables were expressed as mean, and cate-
gorical variables were presented as counts and percen-
tages, and HBV DNA levels were presented as log
transformation. Comparisons between groups of quanti-
tative and qualitative variables were performed using the
student t test and Chi-square test (or Fisher’se x a c tt e s t ) ,
respectively. A P-value of less than 0.05 (two-tailed)
was considered to indicate a significant difference. All
statistical analyses were performed using the SPSS
software package version 13.0 (SPSS Inc., Chicago, IL).
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